Provigil Antitrust Cert. Bid Doomed By Inability To ID Class

By Melissa Lipman · June 11, 2015, 7:33 PM EDT

A Pennsylvania federal judge on Wednesday explained that his recent refusal to let consumers and health plans go forward with class antitrust pay-for-delay claims against Cephalon Inc. and four generic drugmakers...

To view the full article, register now.